SCHEMBL12655352

SCHEMBL12655352

CC(C)(C)OC(=O)N[C@@H]1CCN(c2ccc(N)c(CS(=O)(=O)c3cccc4ccccc34)c2)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SUV39H2 Q9H5I1 6/20 0.43
BRD4 O60885 2/20 0.42
PDE10A Q9Y233 1/20 0.41
BTK Q06187 1/20 0.41
HTR2B P41595 2/20 0.41
HTR6 P50406 2/20 0.41
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
PIM1 P11309 1/20 0.40
PIM3 Q86V86 1/20 0.40
PIM2 Q9P1W9 1/20 0.40
MTNR1A P48039 1/20 0.40
MTNR1B P49286 1/20 0.40
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40
AURKA O14965 3/20 0.39
PDPK1 O15530 3/20 0.39
AURKB Q96GD4 3/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12622493 0.95 CKS1B (0.43) SUV39H2BRD4HTR2BHTR6HDAC3
SCHEMBL12622482 0.87 SUV39H2 (0.44) SUV39H2BRD4PDE10ABTKHDAC3
SCHEMBL1814237 0.87 SUV39H2 (0.41) SUV39H2BRD4PDE10APIM1PIM3
SCHEMBL1813569 0.83 BRD4 (0.44) SUV39H2BRD4BTKHDAC3HDAC1
SCHEMBL1811364 0.82 SIRT6 (0.41) SUV39H2BRD4CKS1BSKP1SKP2
SCHEMBL1814238 0.82 BRD4 (0.43) SUV39H2BRD4PDE10APIM1PIM3
SCHEMBL12622502 0.77 HTR6 (0.47) SUV39H2PDE10ABTKHTR2BHTR6
SCHEMBL12622483 0.76 SUV39H2 (0.42) SUV39H2PDE10APIM1PIM3PIM2
SCHEMBL7242505 0.76 SUV39H2 (0.50) SUV39H2BTKHDAC3HDAC1HDAC2
SCHEMBL15092141 0.76 SUV39H2 (0.48) SUV39H2PDE10ABTKHDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939520-B2 Aminoazacyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands WYETH LLC (US) 2011-05-10 US disclosed
WO-2008144299-A1 5- (AMINOAZACYCLYL) -3-SULFONYL-LH- INDAZOLES AS 5-HYDROXYTRYPTAMINE- 6 LIGANDS FOR THE TREATMENT OF CNS DISORDERS WYETH (US) 2008-11-27 WO disclosed
US-20080293688-A1 AMINOAZACYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS WYETH (US) 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293688-A1 AMINOAZACYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS HTR6, HTR3B, HTR5A SUV39H2 2916/4885BRD4 1543/4885PDE10A 1334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.